Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Scientists decode how cinchona trees build quinine, opening the door to lab-grown production

Scientists decode how cinchona trees build quinine, opening the door to lab-grown production

New Capabilities
By Newzino Staff |

A 250-year biochemical mystery solved — and a path toward sustainable supply of a frontline malaria drug

Today: Complete quinine biosynthetic pathway published in Nature

Overview

For over two centuries, scientists knew that the bark of tropical cinchona trees could cure malaria, but not how the trees actually built the molecule responsible — quinine. Researchers at the Max Planck Institute for Chemical Ecology have now mapped every enzymatic step in that construction, discovering a previously unknown intermediate compound and a surprise catalytic trick that nature uses to assemble quinine's distinctive molecular scaffold. They published the complete biosynthetic pathway in Nature on March 18, 2026.

In This Story

3 Videos
3 People
Sarah E. O'Connor
BL
TZ
2 Orgs
Max Planck Institute for Chemical Ecology World Health Organization
9 Events
4 Key Stats
~$2B
4 Scenarios
Lab-grown quinine reaches commercial scale within a decade
3 Context
Semi-synthetic artemisinin production (2003–2013)

Key Indicators

~$2B
Annual cinchona alkaloid market value
Quinine and related compounds used in malaria treatment, beverages, and industrial chemistry
282M
Malaria cases worldwide in 2024
According to the World Health Organization's 2025 World Malaria Report, with 610,000 deaths
55%
Global quinine supply from the Democratic Republic of the Congo
A single country dominates production, creating significant supply-chain vulnerability
250
Years since scientists began studying cinchona chemistry
The biosynthetic pathway eluded researchers from the late 18th century until this breakthrough

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Sarah E. O'Connor
Sarah E. O'Connor
Senior author of the Nature paper
BL
Blaise Kimbadi Lombe
Co-first author of the Nature paper
TZ
Tingan Zhou
Co-first author of the Nature paper

Organizations Involved

Max Planck Institute for Chemical Ecology
Max Planck Institute for Chemical Ecology
Research Institute
Published the breakthrough research

A German research institute in Jena focused on the chemical interactions between organisms, including the biosynthesis of plant-derived medicinal compounds.
World Health Organization
World Health Organization
International Organization
Sets global malaria treatment guidelines that include quinine

The United Nations agency responsible for international public health, including setting treatment protocols for malaria that determine how quinine is used worldwide.

Timeline

  1. Complete quinine biosynthetic pathway published in Nature

    Breakthrough

    O'Connor's team at the Max Planck Institute publishes the full enzymatic pathway, revealing a novel cinchonium intermediate and a surprising transferase-catalyzed cyclization. They demonstrate that the pathway can be reconstituted in engineered organisms to produce quinine in laboratory settings.

  2. Origin of quinine's methoxy group identified

    Research

    Lombe and colleagues show that quinine's methoxy group traces back to 5-methoxytryptamine as a starting substrate, published in Angewandte Chemie International Edition.

  3. Vinblastine pathway reconstituted in yeast

    Precedent

    Researchers publish the microbial supply chain for the anticancer drug vinblastine in Nature, demonstrating that complex 30-step plant alkaloid pathways can be rebuilt in engineered organisms.

  4. O'Connor lab identifies first biosynthetic enzymes

    Research

    Trenti, Yamamoto, and O'Connor publish the discovery of three enzymes catalyzing early and late steps in quinine biosynthesis, including the dehydrogenase CpDCS and esterase CpDCE.

  5. Semi-synthetic artemisinin reaches commercial production

    Precedent

    Sanofi begins commercial production of the antimalarial artemisinin using engineered yeast — the first successful case of biosynthetic production of a plant-derived antimalarial at industrial scale.

  6. First stereoselective total synthesis achieved

    Synthesis

    Gilbert Stork at Columbia University achieves the first fully stereoselective total synthesis of quinine, settling a decades-long debate about the Woodward-Doering route.

  7. First total synthesis of quinine reported

    Synthesis

    Robert Burns Woodward and William von Eggers Doering report converting quinotoxine to quinine — a formal total synthesis, though not practical for manufacturing.

  8. Quinine isolated from cinchona bark

    Discovery

    French chemists Pierre Joseph Pelletier and Joseph Caventou extract and name the active compound quinine, replacing crude bark with a purified drug.

  9. Cinchona bark reaches Europe

    Discovery

    Spanish Jesuit missionaries bring cinchona bark from Peru to Europe, introducing what will become the world's first effective antimalarial treatment.

Scenarios

1

Lab-grown quinine reaches commercial scale within a decade

Discussed by: Synthetic biology researchers drawing parallels to the artemisinin precedent; Nature News commentary

Following the artemisinin playbook, a pharmaceutical company or nonprofit partnership scales the reconstituted pathway in yeast or another microbial host. Production reaches commercially viable concentrations within five to seven years, and a major manufacturer begins blending biosynthetic quinine with plant-derived supply. This would stabilize prices, reduce dependence on the Democratic Republic of the Congo, and provide a buffer against supply disruptions from conflict or climate events. The artemisinin semi-synthesis effort took roughly a decade from pathway elucidation to Sanofi's commercial production.

2

Discovery accelerates production of related high-value cinchona alkaloids

Discussed by: O'Connor and colleagues in their Nature paper; process chemistry researchers

The pathway knowledge enables biosynthetic production not just of quinine but of cinchonidine and other cinchona alkaloids used as chiral catalysts in pharmaceutical manufacturing. Because these industrial chemicals command higher prices per kilogram than quinine itself, they may reach commercial viability faster, creating an economic engine that cross-subsidizes quinine production. The broader toolkit of newly discovered enzymes also feeds into other monoterpene indole alkaloid research programs.

3

Biosynthetic quinine becomes strategically critical as artemisinin resistance spreads

Discussed by: World Health Organization malaria reports; tropical medicine researchers tracking artemisinin resistance

Partial resistance to artemisinin derivatives — currently concentrated in parts of Southeast Asia and emerging in East Africa — continues spreading across sub-Saharan Africa. As artemisinin-based combination therapies lose efficacy in more regions, quinine's role as a backup severe-malaria treatment grows from safety net to primary option. A biosynthetic supply route becomes not just economically attractive but medically urgent, accelerating investment from global health funders like the Gates Foundation and the Global Fund.

4

Scale-up stalls; plantation-grown quinine remains dominant for decades

Discussed by: Agricultural economists and supply-chain researchers who note the challenges of scaling biosynthetic pathways to industrial volumes

Despite the scientific breakthrough, the metabolic engineering required to produce quinine at competitive cost proves more difficult than expected. Yields in microbial hosts remain too low, or downstream purification costs are prohibitive. Cinchona plantations continue supplying the vast majority of the market, and the pathway knowledge primarily benefits academic research rather than transforming manufacturing. This mirrors the experience with some other complex plant natural products where pathway elucidation did not quickly translate to commercial biosynthesis.

Historical Context

Semi-synthetic artemisinin production (2003–2013)

2003–2013

What Happened

Jay Keasling's lab at the University of California, Berkeley, engineered yeast to produce artemisinic acid — a precursor to the antimalarial artemisinin normally extracted from sweet wormwood plants. The Gates Foundation funded the effort, and Sanofi licensed the technology. By 2013, Sanofi's factory in Garessio, Italy, was producing semi-synthetic artemisinin at commercial scale, reaching 25 grams per liter of artemisinic acid in fermentation.

Outcome

Short Term

Semi-synthetic artemisinin provided a price ceiling and supply buffer during periods when plant-derived supply was disrupted by crop failures or speculation.

Long Term

The project demonstrated that biosynthetic approaches to plant-derived medicines can work at scale, though plant extraction remained dominant when crop yields were high. It became the defining proof-of-concept for synthetic biology in global health.

Why It's Relevant Today

The quinine pathway discovery is at the same starting point the artemisinin effort was in the early 2000s — a complete understanding of the biochemistry, with reconstitution in model organisms demonstrated but commercial-scale production still years away. The artemisinin timeline suggests a decade from pathway to factory.

World War II quinine crisis (1942–1945)

1942–1945

What Happened

When Japan seized the Dutch East Indies in 1942, the Allied powers lost access to roughly 95 percent of the world's quinine supply. Malaria incapacitated more Allied soldiers in the Pacific theater than enemy fire. The crisis spurred emergency programs to develop synthetic alternatives, producing chloroquine and other drugs that would define malaria treatment for decades.

Outcome

Short Term

Tens of thousands of Allied troops suffered from malaria due to quinine shortages. Emergency synthetic drug programs produced chloroquine by war's end.

Long Term

The experience permanently shifted malaria treatment toward synthetic drugs, but also demonstrated the strategic vulnerability of depending on geographically concentrated botanical supply chains — a vulnerability that persists today with Congo-centered production.

Why It's Relevant Today

The wartime quinine crisis is the clearest historical demonstration of what happens when a geographically concentrated botanical supply chain breaks. Today's dependence on the Democratic Republic of the Congo echoes the pre-war dependence on the Dutch East Indies, making the biosynthetic alternative strategically as well as economically significant.

Microbial production of vinblastine precursors (2022)

September 2022

What Happened

A team spanning multiple universities published in Nature the reconstitution of the 30-plus enzymatic steps needed to produce vinblastine — a critical anticancer drug — in engineered yeast. Vinblastine, like quinine, is a complex plant alkaloid that had resisted biosynthetic production for decades.

Outcome

Short Term

The work proved that even extremely long and complex plant biosynthetic pathways could be reconstituted in microbial hosts, though yields remained far below commercial viability.

Long Term

The vinblastine work expanded the frontier of what synthetic biology could attempt, and the enzymes discovered have been reused in other alkaloid engineering projects.

Why It's Relevant Today

Vinblastine and quinine are both complex plant alkaloids in the monoterpene indole alkaloid family. The vinblastine achievement in 2022 demonstrated the feasibility of the same general approach now applied to quinine, and some of the same researchers and techniques were involved in both projects.

Sources

(7)
+1
Nature EurekAlert (Max Planck Institute press release) Phys.org Organic Letters Angewandte Chemie International Edition World Health Organization Nature News & Views